In 2013, Kaiser Permanente developed a risk stratification tool: Hematuria Risk Index (HRI) to further subdivide hematuria patients. Patients were assigned points based on clinical characteristics and three risk groups were developed with varying rates of cancer detection. The low risk (0-4 points) group had a 0-0.3% rate of cancer detection, moderate risk (5-8 points) 1.1-2.5% rate, and high risk (9-11 points) 10.7-11.6%. We applied the HRI stratification model to our cohort of AMH patients in order to externally validate this model and to perform a cost analysis based on the risk stratifications.
INTRODUCTION AND OBJECTIVES:
In 2013, Kaiser Permanente developed a risk stratification tool: Hematuria Risk Index (HRI) to further subdivide hematuria patients. Patients were assigned points based on clinical characteristics and three risk groups were developed with varying rates of cancer detection. The low risk (0-4 points) group had a 0-0.3% rate of cancer detection, moderate risk (5-8 points) 1.1-2.5% rate, and high risk (9-11 points) 10.7-11.6%. We applied the HRI stratification model to our cohort of AMH patients in order to externally validate this model and to perform a cost analysis based on the risk stratifications.
METHODS: A retrospective review was performed of patients who underwent AMH evaluation from 2012 e 2015 at a single institution. After excluding for incomplete evaluation or lack of follow up, 994 patients were included. HRI scores were determined for each patient. Total number of tumors and studies performed in the work up were determined for each of the groups. Cost of tests were estimated based on published Medicare averages from a recent JAMA study.
RESULTS: The Kaiser HRI was validated in our patient cohort and found to be statistically significant for finding cancer in each group (p<0.0001). If no low risk patients were screened, 0 cancers would have been missed and estimated cost would have decreased to $166,252 from $408,376. If no low risk patients as well as no HRI 5&6 patients with either a history of stones or current AC use were screened, cost would have decreased to $130,169 with 0 cancers missed. A receiver operator curve (ROC) generated for HRI and cancer detection had an area under curve (AUC) of 0.885.
CONCLUSIONS: The HRI provided a risk stratification model that would have minimized cost while avoiding missed cancer diagnoses. The low risk group could have avoided work up without missing a single tumor. Other factors such stone history or AC use may be able to be incorporated into the algorithm. The cost benefit analysis in our cohort shows a significant cost savings with minimal loss in cancer detection based on HRI and imaging modality.
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PD67-10 RISKS AND BENEFITS OF FREQUENT SURVEILLANCE CYSTOSCOPY AMONG PATIENTS WITH LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Florian Schroeck*, White River Junction, VT; Kristine Lynch, Salt Lake City, UT; Zhongze Li, Todd MacKenzie, John Seigne, David Han, Lebanon, NH; Douglas Robertson, Brenda Sirovich, Philip Goodney, White River Junction, VT INTRODUCTION AND OBJECTIVES: Surveillance guidelines for patients with low-risk NMIBC recommend no more than 3 cystoscopies in the first 2 years after diagnosis. These recommendations are based on limited evidence and so we sought to assess risks and benefits of frequent surveillance cystoscopy.
METHODS: Using national Department of Veterans Affairs data, we identified patients with low-risk (low grade Ta) NMIBC diagnosed 2005 e 2011 with follow-up through 2014. Procedural codes were used to classify patients as having experienced frequent cystoscopy vs. recommended surveillance (>3 vs. 1-3 cystoscopies in the first 2 years). Using propensity score adjusted models, we estimated the impact of frequent cystoscopy on the number of transurethral resections, the number of resections with no cancer in the specimen, and on risk of progression and bladder cancer mortality.
RESULTS: Among 1,042 patients, 798 (77%) had more frequent cystoscopy than recommended. In adjusted analyses, the frequent cystoscopy group had twice as many transurethral resections (55 vs. 26 per 100 person years; p<0.001) and more than 3 times as many resections with no cancer in the specimen (11 vs. 3 per 100 person years; p<0.001, Figure) . Progression to invasive disease was uncommon, and frequent cystoscopy was associated with shorter time to progression (5% at 1.0 year vs. at 2.3 years; p[0.005). Bladder cancer death was rare and not associated with frequent cystoscopy (3% at 5.4 years vs. at 5.3 years, p[0.820). On sensitivity analyses assuming all patients had intermediate risk disease, 469 patients (45%) had more frequent cystoscopy than recommended (>5 cystoscopies in the first 2 years), and associations between frequent cystoscopy and outcomes remained unchanged.
CONCLUSIONS: This is the first study to quantify risks associated with frequent cystoscopy among patients with low-risk NMIBC: They underwent twice as many transurethral resections and more than three times as many resections with no cancer in the specimen e subjecting patients to avoidable perioperative risks. Potential benefits of frequent cystoscopy are unclear: It was associated with shorter time to progression, which may indicate earlier detection, but it did not prevent progression or bladder cancer death. California (KPNC) and KP Northwest (KPNW)] adopted the new riskstratified guideline in 2012-2013; the third system, KP Washington (KPWA), did not adopt any specific guideline during this period. We compared trends in CT utilization within and between systems among the three risk groups before (2010-11) and after (2014-15) guideline adoption.
RESULTS: Among patients with an episode of care for hematuria evaluation (n[81,291) , the system with highest baseline CT utilization (KPNC) had stable utilization of CT for GH patients (74.7% to 73.8%, p[.2301) and substantial decreases in CT utilization for MHRF (67.6% to 44.5%, p<.0001) and LRMH (52.1% to 43.8%, p<.0001) patients after adoption of the new guideline. The system with lowest baseline CT utilization (KPNW) had guideline-concordant increase in CT utilization for GH patients (22.0% to 68.3%, p<.0001), but also modest guideline-discordant increase in CT for MHRF (21.7% to 36.7%, p<0.001) and LRMH (21.0% to 32.1%, p[.0022) patients. KPWA had more modest changes in CT utilization (GH 55.8% to 58.9%, p[.0567; MHRF 43.0% to 48.7%, p<.0001; LRMH 42.5% to 42.0%, p[.8902 ).
CONCLUSIONS: Adoption of a risk-stratified guideline was associated with differential changes in utilization within and across health systems, sensitive to baseline CT utilization and patient risk factors. Substantial residual variation in utilization suggests additional opportunities for improvement. 
PD67-12 BENEFIT OF EARLY TREATMENT WITH BONE-MODIFYING AGENTS FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH GENITOURINARY CANCER WITH BONE METASTASIS: A LARGE SCALE MULTI-INSTITUTIONAL STUDY
Takuya Owari*, Makito Miyake, Yoshitaka Itami, Kenta Onishi, Nobumichi Tanaka, Kiyohide Fujimoto, Kashihara-shi, Japan INTRODUCTION AND OBJECTIVES: Skeletal-related events (SREs) induced by bone metastasis (BM) can result in reduced QOL, and increased in healthcare burdens. This multi-institutional retrospective study aimed to evaluate the clinical benefit of bonemodifying agents (BMAs), zoledronic acid and denosumab, and identify risk factors of SREs in patients with genitourinary cancer with BM.
METHODS: The study participants included a total of 650 patients with BM of the following cancer types: hormone-sensitive prostate cancer (HSPC; n [ 443), castration-resistant prostate cancer (CRPC; n [ 50), renal cell carcinoma (RCC; n [ 80), and urothelial carcinoma (UC; n [ 77) . Clinical factors at the time of diagnosis of bone metastasis were analyzed. SREs were defined as pathological fracture, spinal cord compression, or the need for palliative radiotherapy/surgery for BM lesions. Early treatment with BMAs was defined as follows: administration of BMAs before the development of SREs and within 6 months from the diagnosis of BM.
